Search | Clinical Trials Finder

Conditions: Renal Insufficiency, Healthy
Interventions: Canagliflozin (JNJ-28431754); Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 3
States / cities: Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee

Conditions: Healthy
Interventions: Divalproex Sodium Extended-Release Tablets 500 mg, Depakote ER® Tablets 500 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Renal Impairment
Interventions: 50 mg Proellex; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Kidney Disease
Interventions: probenecid; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 40 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Men, Male Contraception
Interventions: Dimethandrolone Undecanoate, Placebo; Drug
Lead sponsor: Kimberly Myer; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Torrance, California • Seattle, Washington

Conditions: Urinary Incontinence
Interventions: Investigational prototype device, Comparator device; Device
Lead sponsor: Coloplast A/S; Industry
Eligibility: 18 Years to 110 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Healthy Male Volunteers
Interventions: BMS-986165, Pyrimethamine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteers
Interventions: AZD6244 Dosing Period 1, AZD6244 Dosing Period 2, AZD6244 Dosing Period 3, AZD6244 Dosing Period 4; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Psoriasis
Interventions: Cap SRT2104, Tab SRT2104 slow release, Tab SRT2104 intermediate release, Tab SRT2104 fast release, Selected formulations of SRT2104 from Part 1, Selected formulations of SRT2104 from Part 1 single alternative dose; Drug
Lead sponsor: Sirtris, a GSK Company; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: galeterone; Drug
Lead sponsor: LTN PHARMACEUTICALS, INC.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteer
Interventions: RO5093151, atazanavir, ketoconazole, rifampicin, ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Merritt Island, Florida

Conditions: Normal Healthy Volunteers
Interventions: Placebo, BT-11; Drug
Lead sponsor: NImmune Biopharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: Healthy Volunteers
Interventions: [14C]-BGB-11417; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: 400 mg golimumab or placebo, 200 mg golimumab or placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Topcon Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 6
States / cities: La Jolla, California • Overland Park, Kansas • New York, New York + 1 more

Conditions: Healthy Volunteers; High Cholesterol
Interventions: NNC0385-0434 G, NNC0385-0434 F, NNC0385-0434 B; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Cypress, California • Los Angeles, California

Conditions: Healthy Subjects
Interventions: GSK561679 tablet or solution; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Chronic Renal Insufficiency
Interventions: LHW090, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Tennessee

Conditions: Healthy Volunteer
Interventions: Mosliciguat, 14C mosliciguat, Dry Powder Inhaler; Drug · Device
Lead sponsor: Pulmovant, Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Subjects
Interventions: E2609, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 30 Years to 60 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Volunteer
Interventions: [14C]-EDG-7500; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Renal Impairment, Healthy Volunteers
Interventions: Bocidelpar; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Anniston, Alabama • Rialto, California • Miami, Florida + 1 more

Conditions: Healthy Volunteers
Interventions: AEF0117, Placebo; Drug
Lead sponsor: Aelis Farma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Obesity, Healthy Volunteers
Interventions: S309309, Itraconazole; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function

Food Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg

Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females

Evaluation of Renal Drug Transport in Healthy Volunteers

Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015)

Intermittent Catheterisation on the Bladder Mucosa of Healthy Volunteers With a Prototype Micro Hole Zone Catheter

An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.

A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244

A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers

Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Galeterone

A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers

Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417

A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects

An Age-Stratified Data Collection Study to Establish a Normative Database Using the 3D Optical Coherence Tomography 3D OCT-1000 Mark II

A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II

A Study to Examine the Absorption of GSK561679 in Healthy Male Volunteers

An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction

A Phase 1 Study of Mosliciguat in Healthy, Adult Males

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500

A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People

Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

Effect of Administration of Itraconazole on the Pharmacokinetics of S-309309 in Healthy Participants